Tactile Systems Technology Inc (TCMD) - Net Assets
Based on the latest financial reports, Tactile Systems Technology Inc (TCMD) has net assets worth $217.87 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($272.12 Million) and total liabilities ($54.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Tactile Systems Technology Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $217.87 Million |
| % of Total Assets | 80.06% |
| Annual Growth Rate | 21.01% |
| 5-Year Change | 70.71% |
| 10-Year Change | 267.05% |
| Growth Volatility | 32.57 |
Tactile Systems Technology Inc - Net Assets Trend (2013–2025)
This chart illustrates how Tactile Systems Technology Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Tactile Systems Technology Inc market capitalisation.
Annual Net Assets for Tactile Systems Technology Inc (2013–2025)
The table below shows the annual net assets of Tactile Systems Technology Inc from 2013 to 2025. Also explore how fast is Tactile Systems Technology Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $218.90 Million | +1.06% |
| 2024-12-31 | $216.60 Million | +11.85% |
| 2023-12-31 | $193.64 Million | +59.51% |
| 2022-12-31 | $121.40 Million | -5.32% |
| 2021-12-31 | $128.23 Million | +2.79% |
| 2020-12-31 | $124.75 Million | +10.80% |
| 2019-12-31 | $112.59 Million | +26.13% |
| 2018-12-31 | $89.27 Million | +22.65% |
| 2017-12-31 | $72.79 Million | +22.05% |
| 2016-12-31 | $59.64 Million | +118.63% |
| 2015-12-31 | $27.28 Million | +10.64% |
| 2014-12-31 | $24.66 Million | +11.02% |
| 2013-12-31 | $22.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tactile Systems Technology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6388200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $54.94 Million | 25.10% |
| Common Stock | $22.00K | 0.01% |
| Other Components | $163.94 Million | 74.89% |
| Total Equity | $218.90 Million | 100.00% |
Tactile Systems Technology Inc Competitors by Market Cap
The table below lists competitors of Tactile Systems Technology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
$508.95 Million |
|
Taewoong Co.Ltd
KQ:044490
|
$509.13 Million |
|
Ducgiang Chemicals & Detergent Powder Joint Co
VN:DGC
|
$509.35 Million |
|
Beijing Bewinner Communications Co Ltd
SHE:002148
|
$509.38 Million |
|
Wanma Technology Co Ltd
SHE:300698
|
$508.84 Million |
|
Deluxe Family Co Ltd
SHG:600503
|
$508.79 Million |
|
Matas A/S
CO:MATAS
|
$508.74 Million |
|
Deep Industries Limited
NSE:DEEPINDS
|
$508.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tactile Systems Technology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 216,597,000 to 218,902,000, a change of 2,305,000 (1.1%).
- Net income of 19,086,000 contributed positively to equity growth.
- Share repurchases of 26,561,000 reduced equity.
- Other factors increased equity by 9,780,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $19.09 Million | +8.72% |
| Share Repurchases | $26.56 Million | -12.13% |
| Other Changes | $9.78 Million | +4.47% |
| Total Change | $- | 1.06% |
Book Value vs Market Value Analysis
This analysis compares Tactile Systems Technology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $9.26 | $22.56 | x |
| 2014-12-31 | $1.85 | $22.56 | x |
| 2015-12-31 | $2.04 | $22.56 | x |
| 2016-12-31 | $3.54 | $22.56 | x |
| 2017-12-31 | $3.86 | $22.56 | x |
| 2018-12-31 | $4.61 | $22.56 | x |
| 2019-12-31 | $5.73 | $22.56 | x |
| 2020-12-31 | $6.45 | $22.56 | x |
| 2021-12-31 | $6.50 | $22.56 | x |
| 2022-12-31 | $6.05 | $22.56 | x |
| 2023-12-31 | $8.36 | $22.56 | x |
| 2024-12-31 | $8.97 | $22.56 | x |
| 2025-12-31 | $9.40 | $22.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tactile Systems Technology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.79%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 1.25x
- Recent ROE (8.72%) is above the historical average (4.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.21% | 8.49% | 1.27x | 1.32x | $935.30K |
| 2014 | 8.40% | 4.34% | 1.52x | 1.28x | $-395.50K |
| 2015 | 5.11% | 2.22% | 1.70x | 1.36x | $-1.33 Million |
| 2016 | 4.83% | 3.41% | 1.14x | 1.24x | $-3.08 Million |
| 2017 | 8.04% | 5.36% | 1.24x | 1.22x | $-1.42 Million |
| 2018 | 7.42% | 4.61% | 1.34x | 1.20x | $-2.30 Million |
| 2019 | 9.74% | 5.79% | 1.25x | 1.35x | $-288.50K |
| 2020 | -0.50% | -0.33% | 1.07x | 1.40x | $-13.10 Million |
| 2021 | -9.21% | -5.68% | 0.85x | 1.90x | $-24.63 Million |
| 2022 | -14.72% | -7.24% | 0.97x | 2.10x | $-30.01 Million |
| 2023 | 14.73% | 10.39% | 0.98x | 1.45x | $9.15 Million |
| 2024 | 7.83% | 5.79% | 0.98x | 1.38x | $-4.70 Million |
| 2025 | 8.72% | 5.79% | 1.20x | 1.25x | $-2.80 Million |
Industry Comparison
This section compares Tactile Systems Technology Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $638,670,729
- Average return on equity (ROE) among peers: -85.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tactile Systems Technology Inc (TCMD) | $217.87 Million | 14.21% | 0.25x | $508.87 Million |
| Abbott Laboratories (ABT) | $4.40 Billion | 38.41% | 1.14x | $177.76 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $11.55 Million |
| Aethlon Medical Inc (AEMD) | $-9.30 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $780.04 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.88 Million |
| Allurion Technologies, Inc. (ALUR) | $-32.31 Million | 0.00% | 0.00x | $1.19 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.16 Million |
| Artivion Inc (AORT) | $79.80 Million | -34.79% | 0.33x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $127.64 Million |
About Tactile Systems Technology Inc
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression dev… Read more